Post date
16/12/2025
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Post date
10/07/2025
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
Post date
10/07/2025
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
Post date
25/06/2025
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease, obesity and diabetes, will enable Danone to expand further into gut health
Deal marks
Post date
24/06/2025
Novadip is developing NVD003, an autologous therapy derived from adipose stem cells, as a potential single treatment to save limbs and restore mobility in patients with CPT.
The RMAT designation is
Post date
14/02/2025
At 12 months, 100% of participants with distal radius fractures treated in trial with NVDX3, an allogenic stem-cell derived bone graft material, demonstrated durable bone union
No adverse events
Post date
14/02/2025
BiocSol succeeds in its ambition to raise a total of €10M since inception to fast-track the development of its sustainable crop protection solutions - testament to the sector’s growing interest in its
Post date
17/12/2024
Dr. Gaspar brings invaluable expertise to gene-editing pioneering company Eligo as it prepares for clinical trials with the world’s first topical CRISPR treatment.
Eligo also strengthens its investor
Post date
17/12/2024
Generare uses a novel cloning technique to break down microbial DNA and accelerate the discovery of potential new natural molecules for drugs.
Natural Products (NPs) have led to 500+ drugs, but
Post date
20/11/2024
BiocSol secures €5.2M seed funding to transform sustainable crop protection with next generation microbial-based solutions, targeting total €10M in funding by year-end
- Built on decade of research
Post date
18/11/2024
ATB Therapeutics Raises €54 Million Series A Financing to Propel Innovative Antibody Payload Technology into Clinical Development
• Financing co-led by EQT Life Sciences and MRL Ventures Fund (MRLV
Post date
13/09/2024
- New investment from Luxembourg Future Fund 2 brings total funding to €75M, well above original target
- Deal underlines VIVES’ know-how in connecting academic research and innovative projects with